Ambrosia Bio
Enzyme-Based Bioprocess Technology for Low-Calorie Sugar Alternatives
Company Overview
Snapshot
Founded in September 2020 by Ziv Zwighaft, Ambrosia Bio operates with 1–10 employees. The company has raised $1.52M across 8 funding rounds from 2 investors. In March 2022, Ambrosia Bio secured SAFE funding from Brinc.
Business overview
Ambrosia Bio develops enzyme technology to convert industrial sugars into low-calorie rare sugars like Allulose. The company's core product is a disruptive enzyme platform designed to create superior enzymes for sugar reduction without compromising the consumption experience. Ambrosia Bio operates on a B2B model, providing tailored engineering solutions to leading sugar and Food & Beverage manufacturers, addressing the demand for rare sugars and novel ingredients within the Agriculture & Food Technologies sector.
Strategic signal
In June 2022, Ambrosia Bio was recognized as a winner in an industrial biotech start-up contest by TWB. This achievement signals external validation of the company's innovative enzyme technology and its potential to impact the food industry, suggesting a positive trajectory for its low-calorie sugar alternative solutions.
Company Intelligence Q&A
- What is Ambrosia Bio's core technology?
- Ambrosia Bio has developed a disruptive enzyme technology platform that converts obesity-promoting industrial sugars into minimal-calorie rare sugars such as Allulose.
- When was Ambrosia Bio founded and by whom?
- Ambrosia Bio was founded in September 2020 by Ziv Zwighaft, who serves as Co-founder & CEO.
- What recognition did Ambrosia Bio receive in June 2022?
- In June 2022, Ambrosia Bio was announced as one of the winners in an industrial biotech start-up contest by TWB.
- What type of business model does Ambrosia Bio employ?
- Ambrosia Bio operates on a B2B business model, providing tailored engineering solutions to sugar and Food & Beverage manufacturers.